A preparation method and application of freeze-dried instant recombinant human albumin

Through ultrafiltration and drying treatment combined with the use of acetyl tryptophan, sodium octanoate and poloxamer 188, the poor solubility and stability of recombinant human albumin were solved, rapid dissolution and long-term stability were achieved, and it was suitable for promoting transportation.

CN118652320BActive Publication Date: 2024-11-05TONGHUA ANRATE BIOPHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411124378.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-05
Estimated Expiration
2044-08-16

AI Technical Summary

Technical Problem

Recombinant human albumin has poor solubility and slow solubility in water, and poor long-term storage stability.

Method used

After ultrafiltration, liquid change and desalting treatment, acetyl tryptophan, sodium octanoate and poloxamer 188 are added as lyophilized protective agent and stabilizer. After prefreezing, sublimation and analysis drying, instant recombinant human albumin is prepared. Freeze-dried.

Benefits of technology

It significantly improves the dissolution rate and redissolution clarity of recombinant human albumin in water, extends the stability of lyophilized powder, can be completely dissolved in 30 seconds at a concentration of 200mg/ml, and store six in high temperature and high humidity environment. Monthly invariance and stable chemical properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118652320B_ABST
    Figure CN118652320B_ABST
Patent Text Reader

Abstract

The present invention provides a method for preparing a fast-dissolving recombinant human albumin freeze-dried powder and its application, and relates to the field of protein engineering. The present invention provides a low-cost freeze-dried formula and freeze-dried process, which can solve the problem of poor solubility and slow dissolution of recombinant human albumin in water. The recombinant human albumin freeze-dried powder prepared by the present invention can be completely dissolved within 30 seconds at a concentration of 200 mg / ml, and the freeze-dried powder can be stored in a high temperature and high humidity environment for six months without denaturation, and the shelf life is more than 5 years when stored in a cool and dry place, and the chemical properties are stable, which is suitable for promotion and transportation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of protein engineering, and in particular to a preparation method and application of freeze-dried instant recombinant human albumin. Background Art

[0002] Proteins are composed of 20 common amino acids connected by peptide bonds, and their biological functions and activities depend on the natural conformation of proteins. However, sometimes proteins cannot be stored in liquids for a long time, especially heat-sensitive proteins and proteins that are unstable in aqueous solutions. Therefore, drying and removing moisture from proteins is an important means of preserving protein samples, and freeze-drying is the preferred method for drying proteins. Compared with liquid proteins, freeze-drying proteins to make freeze-dried powders not only makes the protein properties more stable, but also makes it easier to store, package and carry.

[0003] Human serum albumin (HSA) is the protein with the highest content in plasma, accounting for about half of the total plasma protein. Human serum albumin is a monomeric protein produced by the liver. Mature human serum albumin contains 585 amino acid residues and has a molecular weight of 66KD. Human serum albumin products are therapeutic drugs extracted from human plasma and have many important physiological functions: 1. Maintaining plasma colloidal osmotic pressure and regulating body fluid distribution; 2. Having ligand binding ability, it can store and transport endogenous and exogenous substances; 3. Nutritional effect. It is mainly used for the treatment of: 1. Shock caused by blood loss and trauma, 2. Increased intracranial pressure caused by cerebral edema and injury; 3. Edema or ascites caused by cirrhosis and kidney disease. Due to the limitation of plasma raw materials, my country's blood-derived human serum albumin (pHSA) cannot meet domestic demand. In recent years, half of my country's human serum albumin needs to be imported. Recombinant human serum albumin (rHSA) can alleviate the current tight supply of human serum albumin. The use of genetic recombination technology to produce recombinant human albumin can free the production of albumin from the limitations of raw materials, and at the same time avoid the contamination of pathogenic microorganisms introduced by plasma raw materials.

[0004] However, the long-term storage and freeze-drying technology of recombinant human albumin still needs to be improved. Summary of the invention

[0005] The purpose of the present invention is to provide a freeze-drying preparation method of recombinant human albumin, which can solve the problems of poor solubility, slow dissolution and poor long-term storage stability of recombinant human albumin in water.

[0006] On the one hand, the present application provides a method for preparing a lyophilized instant recombinant human albumin, the method comprising the following steps:

[0007] Step 1, ultrafiltration, liquid replacement, and desalination treatment of the recombinant human albumin solution to obtain a mixed solution;

[0008] Step 2: Add a lyoprotectant and a stabilizer to the mixed solution, stir and dissolve evenly, sterilize to obtain a filtrate, pre-freeze the filtrate, sublimate and dry it, and obtain the instant recombinant human albumin lyophilized product; the lyoprotectant is acetyltryptophan, and the stabilizer is sodium octanoate and poloxamer.

[0009] Furthermore, the mass ratio of the recombinant human albumin, acetyltryptophan, sodium octanoate and poloxamer 188 is (50-250): (0-30): (0-40): (0.2-21).

[0010] Preferably, the mass ratio of the recombinant human albumin, acetyltryptophan, sodium octanoate and poloxamer 188 is (100-250):(15-30):(20-40):(10-21).

[0011] Preferably, the mass ratio of the recombinant human albumin, acetyltryptophan, sodium octanoate and poloxamer 188 is 200:15:20:10.

[0012] Furthermore, the concentration of the recombinant human albumin is 50-250 mg / ml; and / or the concentration of the acetyltryptophan is 0-30 mg / ml; and / or the concentration of the sodium octanoate is 0-40 mg / ml; and / or the poloxamer is poloxamer 188, with a concentration of 0.2-21 mg / ml.

[0013] Preferably, the concentration of the recombinant human albumin is 100-250 mg / ml; and / or the concentration of the acetyltryptophan is 15-30 mg / ml; and / or the concentration of the sodium octanoate is 20-40 mg / ml; and / or the poloxamer is poloxamer 188, with a concentration of 10-21 mg / ml.

[0014] Wherein, the concentration of the recombinant human albumin may be any one of 50 mg / ml, 60 mg / ml, 70 mg / ml, 80 mg / ml, 90 mg / ml, 100 mg / ml, 110 mg / ml, 120 mg / ml, 130 mg / ml, 140 mg / ml, 150 mg / ml, 160 mg / ml, 170 mg / ml, 180 mg / ml, 190 mg / ml, 200 mg / ml, 210 mg / ml, 220 mg / ml, 230 mg / ml, 240 mg / ml and 250 mg / ml.

[0015] The concentration of the acetyltryptophan can be any value among 0mg / ml, 2mg / ml, 3mg / ml, 4mg / ml, 5mg / ml, 6mg / ml, 7mg / ml, 8mg / ml, 9mg / ml, 10mg / ml, 11mg / ml, 12mg / ml, 13mg / ml, 14mg / ml, 15mg / ml, 16mg / ml, 17mg / ml, 18mg / ml, 19mg / ml, 20mg / ml, 21mg / ml, 22mg / ml, 23mg / ml, 24mg / ml, 25mg / ml, 26mg / ml, 27mg / ml, 28mg / ml, 29mg / ml and 30mg / ml.

[0016] The concentration of the sodium octanoate can be any value of 0mg / ml, 2mg / ml, 3mg / ml, 4mg / ml, 5mg / ml, 6mg / ml, 7mg / ml, 8mg / ml, 9mg / ml, 10mg / ml, 11mg / ml, 12mg / ml, 13mg / ml, 14mg / ml, 15mg / ml, 16mg / ml, 17mg / ml, 18mg / ml, 19mg / ml, 20mg / ml, 21mg / ml, 22mg / ml, 23mg / ml, 24 mg / ml, 25 mg / ml, 26 mg / ml, 27mg / ml, 28mg / ml, 29mg / ml, 30mg / ml, 31mg / ml, 32mg / ml, 33mg / ml, 34mg / ml, 35mg / ml, 36mg / ml, 37mg / ml, 38mg / ml, 39mg / ml and 40mg / ml.

[0017] The poloxamer is poloxamer 188, and the concentration can be any value among 0.2mg / ml, 2mg / ml, 3mg / ml, 4mg / ml, 5mg / ml, 6mg / ml, 7mg / ml, 8mg / ml, 9mg / ml, 10mg / ml, 11mg / ml, 12mg / ml, 13mg / ml, 14mg / ml, 15mg / ml, 16mg / ml, 17mg / ml, 18mg / ml, 19mg / ml, 20mg / ml and 21mg / ml.

[0018] Preferably, the concentration of the recombinant human albumin is 200 mg / ml, the concentration of the acetyltryptophan is 15 mg / ml, the concentration of the sodium octanoate is 20 mg / ml, and the concentration of the poloxamer 188 is 10 mg / ml.

[0019] Furthermore, the pre-freezing treatment temperature is -55°C to -30°C, and the pre-freezing treatment time is 2 to 6 hours; preferably, -40°C for 4 hours.

[0020] The pre-freezing treatment temperature may be any value among -55°C, -54°C, -53°C, -52°C, -51°C, -50°C, -49°C, -48°C, -47°C, -46°C, -45°C, -44°C, -43°C, -42°C, -41°C, -40°C, -39°C, -38°C, -37°C, -36°C, -35°C, -34°C, -33°C, -32°C, -31°C, and -30°C.

[0021] The pre-freezing treatment time can be any value among 2h, 3h, 4h, 5h and 6h.

[0022] The pre-freezing treatment is carried out under normal pressure.

[0023] Further, the sublimation drying includes a first sublimation drying treatment and a second sublimation drying treatment; preferably, the temperature of the first sublimation drying treatment is -30°C~-20°C, the pressure of the first sublimation drying treatment is 5~35Pa, and the time of the first sublimation drying treatment is 10~25h; preferably, the temperature of the second sublimation drying treatment is -25°C~-10°C, the pressure of the second sublimation drying treatment is 5~35Pa, and the time of the second sublimation drying treatment is 10~15h.

[0024] The temperature of the first sublimation drying treatment may be any value among -30°C, -29°C, -28°C, -27°C, -26°C, -25°C, -24°C, -23°C, -22°C, -21°C, and -20°C.

[0025] The pressure of the first sublimation drying treatment may be any value among 5Pa, 6Pa, 7Pa, 8Pa, 9Pa, 10Pa, 20Pa, 25Pa, 30Pa, and 35Pa.

[0026] The time of the first sublimation drying treatment can be any value among 10 hours, 15 hours, 20 hours and 25 hours.

[0027] The temperature of the second sublimation drying treatment may be any value among -25°C, -24°C, -23°C, -22°C, -21°C, -20°C, -19°C, -18°C, -17°C, -16°C, -15°C, -14°C, -13°C, -12°C, -11°C, and -10°C.

[0028] The pressure of the second sublimation drying process may be any value among 5Pa, 6Pa, 7Pa, 8Pa, 9Pa, 10Pa, 20Pa, 25Pa, 30Pa, and 35Pa.

[0029] The time of the second sublimation drying treatment can be any value among 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, and 15 hours.

[0030] Preferably, the temperature of the first sublimation drying treatment is -30°C, the pressure of the first sublimation drying treatment is 35 Pa, and the time of the first sublimation drying treatment is 25 hours; the temperature of the second sublimation drying treatment is -20°C, the pressure of the second sublimation drying treatment is 35 Pa, and the time of the second sublimation drying treatment is 15 hours.

[0031] Furthermore, the analytical drying includes a first analytical drying treatment and a second analytical drying treatment; preferably, the temperature of the first analytical drying treatment is 0°C~10°C, the pressure of the first analytical drying treatment is 10~20Pa, and the time of the first analytical drying treatment is 5~25h; preferably, the temperature of the second analytical drying treatment is 10°C~20°C, the pressure of the second analytical drying treatment is 2~5Pa, and the time of the second analytical drying treatment is 5~15h.

[0032] The temperature of the first analytical drying process may be any value among 0°C, 1°C, 2°C, 3°C, 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, and 10°C.

[0033] The pressure of the first analytical drying process may be any value among 10Pa, 15Pa, 20Pa, and 25Pa.

[0034] The time of the first analytical drying process may be any value among 5 h, 10 h, 15 h, 20 h, and 25 h.

[0035] The temperature of the second analytical drying process may be any value among 10°C, 11°C, 12°C, 13°C, 14°C, 15°C, 16°C, 17°C, 18°C, 19°C, and 20°C.

[0036] The pressure of the second sublimation drying process can be any value among 2Pa, 3Pa, 4Pa, and 5Pa.

[0037] The time of the second sublimation drying treatment may be any value among 5 h, 6 h, 7 h, 8 h, 9 h, 10 h, 11 h, 12 h, 13 h, 14 h, and 15 h.

[0038] Preferably, the temperature of the first analytical drying treatment is 10°C, the pressure of the first analytical drying treatment is 20 Pa, and the time of the first analytical drying treatment is 15 hours; the temperature of the second analytical drying treatment is 20°C, the pressure of the second analytical drying treatment is 5 Pa, and the time of the second analytical drying treatment is 15 hours.

[0039] Furthermore, the pore size of the ultrafiltration membrane used in the ultrafiltration is 1~50KDa; preferably, 30KDa.

[0040] In a preferred embodiment, the method comprises the following steps:

[0041] Step 1: ultrafiltration the recombinant human albumin solution, the pore size of the ultrafiltration membrane is 1-50KDa, and the solution is replaced and desalted to obtain a mixed solution;

[0042] Step 2, adding acetyltryptophan, sodium octanoate and poloxamer 188 to the mixed solution, stirring and dissolving evenly, sterilizing to obtain a filtrate, and performing pre-freezing treatment, sublimation drying and analytical drying on the filtrate to obtain the instant recombinant human albumin freeze-dried product;

[0043] Wherein, the pre-freezing treatment temperature is -55°C to -30°C, and the pre-freezing treatment time is 2 to 6 hours;

[0044] The sublimation drying includes a first sublimation drying process and a second sublimation drying process; the temperature of the first sublimation drying process is -30°C to -20°C, the pressure of the first sublimation drying process is 5~35Pa, and the time of the first sublimation drying process is 10~25h; the temperature of the second sublimation drying process is -20°C to -10°C, the pressure of the second sublimation drying process is 5~35Pa, and the time of the second sublimation drying process is 10~15h;

[0045] The analytical drying includes a first analytical drying treatment and a second analytical drying treatment; the temperature of the first analytical drying treatment is 0°C~10°C, the pressure of the first analytical drying treatment is 10~20Pa, and the time of the first analytical drying treatment is 5~15h; the temperature of the second analytical drying treatment is 10°C~20°C, the pressure of the second analytical drying treatment is 2~5Pa, and the time of the second analytical drying treatment is 5~15h.

[0046] Preferably, the treatment conditions for ultrafiltration, fluid exchange and desalination are: inlet pressure: 30 psi, inlet tangential flow rate: 8.0 LMM, TMP ≤ 25 psi, the sample is dialyzed according to constant volume dialysis, and the permeate conductivity is < 50 μs / cm.

[0047] On the other hand, the present application also provides fast-dissolving recombinant human albumin lyophilized prepared by the method.

[0048] The dissolution time of the fast-soluble recombinant human albumin at a concentration of 200 mg / ml is less than 200 s. Preferably, the dissolution time of the fast-soluble recombinant human albumin at a concentration of 200 mg / ml is less than 30 s.

[0049] The instant recombinant human albumin freeze-dried product has stable chemical properties and can be stored in a cool and dry place for 5 years, and can be stored in a high temperature and high humidity environment with a temperature of 60° C. and a humidity of 75% for six months.

[0050] The lyophilized powder prepared in the present application significantly improves the dissolution rate and reconstitution clarity of recombinant human albumin in water, while also improving the stability of the recombinant human albumin lyophilized powder.

[0051] The instant recombinant human albumin freeze-dried product can be completely dissolved within 30 seconds at a concentration of 200 mg / ml; it does not change when stored for six months in an environment of 60° C. and 75% humidity; it has a shelf life of more than 5 years when stored in a cool and dry place, and its chemical properties are stable.

[0052] On the other hand, the present application also provides a freeze-dried product comprising the instant recombinant human albumin.

[0053] The product described in this application may also be added with conventional lyophilized preparation excipients.

[0054] On the other hand, the present application also provides the use of the method in improving the freeze-dried dissolution rate and / or stability of recombinant human albumin.

[0055] The present invention has the following beneficial effects:

[0056] The present invention provides a low-cost freeze-drying formula and freeze-drying process, which can solve the problem of poor solubility and slow dissolution of recombinant human albumin in water. The present invention adopts acetyltryptophan as a freeze-drying protective agent, sodium octanoate and poloxamer 188 as stabilizers for the first time to prepare freeze-dried recombinant human albumin, and the three cooperate to improve the stability and solubility of freeze-dried recombinant albumin. A new preparation process is provided for freeze-dried recombinant human albumin.

[0057] The recombinant human albumin lyophilized powder prepared by the present invention can be completely dissolved within 30 seconds at a concentration of 200 mg / ml, and the lyophilized powder can be stored in a high temperature and high humidity environment for six months without being denatured, and has a shelf life of more than 5 years when stored in a cool and dry place. The chemical properties are stable and the powder is suitable for promotion and transportation. BRIEF DESCRIPTION OF THE DRAWINGS

[0058] The drawings described herein are used to provide a further understanding of the present application and constitute a part of the present application. The illustrative embodiments of the present application and their descriptions are used to explain the present application and do not constitute an improper limitation on the present application. In the drawings:

[0059] Figure 1 15% SDS-PAGE patterns of Examples 1 to 6, wherein: Figure 1 Lanes 1 to 6 are the reduced electrophoresis diagrams of Examples 1-6, respectively. Figure 1 Lanes 9 to 14 are the non-reduced electrophoresis diagrams of Examples 1 to 6, respectively. Figure 1 Lane 7 is albumin standard. Figure 1 Lane 8 is the Marker electrophoresis diagram;

[0060] Figure 2 15% SDS-PAGE patterns of Examples 7 to 9, wherein: Figure 2 Lanes 1 to 4 are the reduced electrophoresis diagrams of Examples 7-9, respectively. Figure 2 Lanes 5 to 8 are the reduced electrophoresis images of Examples 7 to 9, respectively. Figure 2 Lane 9 is albumin standard. Figure 1 Lane 10 is the Marker electrophoresis diagram;

[0061] Figure 3 15% SDS-PAGE patterns of Examples 10 to 12, wherein: Figure 3 Lanes 1 to 3 are the reduced electrophoresis images of Examples 10 to 12, respectively. Figure 3 Lanes 4 to 6 are the reduced electrophoresis images of Examples 10 to 12, respectively. Figure 3 Lane 7 is albumin standard. Figure 3 Lane 8 is the Marker electrophoresis diagram;

[0062] Figure 4 is the Marker map;

[0063] Figure 5 This is the HPLC spectrum of the accelerated June lyophilized powder of Example 1;

[0064] Figure 6 This is the HPLC spectrum of the accelerated June lyophilized powder of Example 2;

[0065] Figure 7 This is the HPLC spectrum of the accelerated June lyophilized powder of Example 3;

[0066] Figure 8 This is the HPLC spectrum of the accelerated June lyophilized powder of Example 4;

[0067] Fig. 9 This is the HPLC spectrum of the accelerated June lyophilized powder of Example 5;

[0068] Fig.10 This is the HPLC spectrum of the accelerated June lyophilized powder of Example 6;

[0069] Fig.11 This is the HPLC spectrum of the accelerated June lyophilized powder of Example 7;

[0070] Fig.12 This is the HPLC spectrum of the accelerated June lyophilized powder of Example 8;

[0071] Fig.13 This is the HPLC spectrum of the accelerated June lyophilized powder of Example 9;

[0072] Fig.14 This is the HPLC spectrum of the accelerated June lyophilized powder of Example 10;

[0073] Fig.15 This is the HPLC spectrum of the accelerated June lyophilized powder of Example 11;

[0074] Fig.16 This is the HPLC spectrum of the accelerated June lyophilized powder of Example 12. DETAILED DESCRIPTION

[0075] In order to more clearly explain the overall concept of the present application, the following is described in detail in conjunction with the accompanying drawings of the specification by way of embodiment. In the following description, a large number of specific details are provided to provide a more thorough understanding of the present invention. However, it is obvious to those skilled in the art that the present invention can be implemented without one or more of these details. In other examples, in order to avoid confusion with the present invention, some technical features well known in the art are not described.

[0076] If no specific conditions are specified in the examples, the experiments were carried out according to conventional conditions or conditions recommended by the manufacturer.

[0077] Among them, recombinant human albumin product number: ART101L (Tonghua Anruite Biopharmaceutical Co., Ltd.), acetyltryptophan was purchased from Jinyao Pharmaceutical Co., Ltd., Lot: AYXS0230101, sodium octanoate was purchased from Chengdu Huayi Pharmaceutical Excipients Manufacturing Co., Ltd., Lot: 20230301, and poloxamer 188 was purchased from BASF (China) Co., Ltd., Lot: GNH18221B.

[0078] Unless otherwise specified, in the following embodiments, the reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially.

[0079] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in microbiology, biochemistry, analytical chemistry, cell culture, and related fields conventional in the technical field.

[0080] In addition, the "water" mentioned in the present invention includes any feasible water that can be used in the art, such as deionized water, distilled water, ion exchange water, double distilled water, high-purity water, and purified water.

[0081] In the following examples, unless otherwise specified, % means wt%, i.e., weight percentage, and the weight (mass) parts used in the following examples are all measured in mg / ml.

[0082] Example 1

[0083] A formula of a fast-dissolving recombinant human albumin lyophilized powder is shown in Table 1 below.

[0084] Table 1

[0085]

[0086] (1) ultrafiltration, liquid exchange, and desalination of the recombinant human albumin solution into purified water (inlet pressure: 30 psi, inlet tangential flow rate: 8.0 LMM, TMP ≤ 25 psi), and diafiltration of the sample according to constant volume dialysis, with a permeate conductivity of <50 μs / cm, to obtain a mixed solution (the recombinant human albumin concentration in the mixed solution is 200 mg / ml), wherein the pore size of the ultrafiltration membrane used in the ultrafiltration treatment is 30 KDa;

[0087] (2) Add acetyltryptophan, sodium octanoate and poloxamer 188 to the mixed solution of step (1), stir and dissolve evenly, then sterilize and filter to obtain a filtrate (the concentration of acetyltryptophan is 15 mg / ml, the concentration of sodium octanoate is 20 mg / ml, and the concentration of poloxamer 188 is 10 mg / ml), pre-freeze the filtrate, and then perform sublimation drying and analytical drying to obtain the instant recombinant human albumin lyophilized powder.

[0088] The freeze-drying parameters are shown in Table 2 below.

[0089] Table 2

[0090]

[0091] Example 2

[0092] A formula of a fast-dissolving recombinant human albumin lyophilized powder is shown in Table 3 below.

[0093] Table 3

[0094]

[0095] Referring to Table 3, a method for preparing instant recombinant human albumin lyophilized powder comprises the following steps:

[0096] (1) ultrafiltration, liquid exchange, and desalination of the recombinant human albumin solution into purified water (inlet pressure: 30 psi, inlet tangential flow rate: 8.0 LMM, TMP ≤ 25 psi), and diafiltration of the sample according to constant volume dialysis, with a permeate conductivity of <50 μs / cm, to obtain a mixed solution (the recombinant human albumin concentration in the mixed solution is 200 mg / ml), wherein the pore size of the ultrafiltration membrane used in the ultrafiltration treatment is 30 KDa;

[0097] (2) Add poloxamer 188 to the mixed solution of step (1), stir to dissolve evenly, then sterilize and filter to obtain a filtrate (the concentration of poloxamer 188 is 10 mg / ml), pre-freeze the filtrate, and then perform sublimation drying and analytical drying to obtain the instant recombinant human albumin lyophilized powder.

[0098] The freeze-drying parameters are shown in Table 4 below.

[0099] Table 4

[0100]

[0101] Example 3

[0102] A formula of a fast-dissolving recombinant human albumin lyophilized powder is shown in Table 5 below.

[0103] Table 5

[0104]

[0105] As shown in Table 5, a method for preparing a fast-dissolving recombinant human albumin lyophilized powder comprises the following steps:

[0106] (1) ultrafiltration, liquid exchange, and desalination of the recombinant human albumin solution into purified water (inlet pressure: 30 psi, inlet tangential flow rate: 8.0 LMM, TMP ≤ 25 psi), and diafiltration of the sample according to constant volume dialysis, with a permeate conductivity of <50 μs / cm, to obtain a mixed solution (the recombinant human albumin concentration in the mixed solution is 200 mg / ml), wherein the pore size of the ultrafiltration membrane used in the ultrafiltration treatment is 30 KDa;

[0107] (2) Add acetyltryptophan, sodium octanoate and poloxamer 188 to the mixed solution of step (1), stir and dissolve evenly, then sterilize and filter to obtain a filtrate (the concentration of acetyltryptophan is 30 mg / ml, the concentration of sodium octanoate is 40 mg / ml, and the concentration of poloxamer 188 is 21 mg / ml), pre-freeze the filtrate, and then perform sublimation drying and analytical drying to obtain the instant recombinant human albumin lyophilized powder.

[0108] The freeze-drying parameters are shown in Table 6.

[0109] Table 6

[0110]

[0111] Example 4

[0112] A formula of a fast-dissolving recombinant human albumin lyophilized powder is shown in Table 7 below.

[0113] Table 7

[0114]

[0115] Referring to Table 7, a method for preparing instant recombinant human albumin lyophilized powder comprises the following steps:

[0116] (1) ultrafiltration, liquid exchange, and desalination of the recombinant human albumin solution into purified water (inlet pressure: 30 psi, inlet tangential flow rate: 8.0 LMM, TMP ≤ 25 psi), and diafiltration of the sample according to constant volume dialysis, with a permeate conductivity of <50 μs / cm, to obtain a mixed solution (the recombinant human albumin concentration in the mixed solution is 200 mg / ml), wherein the pore size of the ultrafiltration membrane used in the ultrafiltration treatment is 30 KDa;

[0117] (2) Sodium octanoate and poloxamer 188 are added to the mixed solution of step (1), stirred and dissolved uniformly, and then sterilized and filtered to obtain a filtrate (the concentration of sodium octanoate is 20 mg / ml, and the concentration of poloxamer 188 is 0.2 mg / ml), and the filtrate is pre-frozen, and then sublimated and dried, and analytically dried to obtain the instant recombinant human albumin lyophilized powder.

[0118] The freeze-drying parameters are shown in Table 8.

[0119] Table 8

[0120]

[0121] Example 5

[0122] A formula of a fast-dissolving recombinant human albumin lyophilized powder is shown in Table 9 below.

[0123] Table 9

[0124]

[0125] Referring to Table 9, a method for preparing instant recombinant human albumin lyophilized powder comprises the following steps:

[0126] (1) ultrafiltration, liquid exchange, and salt treatment of the recombinant human albumin solution into purified water (inlet pressure: 30 psi, inlet tangential flow rate: 8.0 LMM, TMP ≤ 25 psi), and diafiltration of the sample according to constant volume dialysis, with a permeate conductivity of <50 μs / cm, to obtain a mixed solution (the recombinant human albumin concentration in the mixed solution is 250 mg / ml), wherein the pore size of the ultrafiltration membrane used in the ultrafiltration treatment is 30 KDa;

[0127] (2) Add acetyltryptophan, sodium octanoate and poloxamer 188 to the mixed solution of step (1), stir and dissolve them uniformly, then sterilize and filter to obtain a filtrate (acetyltryptophan concentration is 15 mg / ml, sodium octanoate concentration is 20 mg / ml, and poloxamer 188 concentration is 10 mg / ml), pre-freeze the filtrate, and then perform sublimation drying and analytical drying to obtain the instant recombinant human albumin lyophilized powder.

[0128] The freeze-drying parameters are shown in Table 10.

[0129] Table 10

[0130]

[0131] Example 6

[0132] A formula of a fast-dissolving recombinant human albumin lyophilized powder is shown in Table 11 below.

[0133] Table 11

[0134]

[0135] Referring to Table 11, a method for preparing instant recombinant human albumin lyophilized powder comprises the following steps:

[0136] (1) ultrafiltration, liquid exchange, and salt treatment of the recombinant human albumin solution into purified water (inlet pressure: 30 psi, inlet tangential flow rate: 8.0 LMM, TMP ≤ 25 psi), and diafiltration of the sample according to constant volume dialysis, with a permeate conductivity of <50 μs / cm, to obtain a mixed solution (the recombinant human albumin concentration in the mixed solution is 250 mg / ml), wherein the pore size of the ultrafiltration membrane used in the ultrafiltration treatment is 30 KDa;

[0137] (2) Add acetyltryptophan, sodium octanoate and poloxamer 188 to the mixed solution of step (1), stir and dissolve evenly, then sterilize and filter to obtain a filtrate (acetyltryptophan concentration is 30 mg / ml, sodium octanoate concentration is 40 mg / ml, and poloxamer 188 concentration is 21 mg / ml), pre-freeze the filtrate, and then perform sublimation drying and analytical drying to obtain the instant recombinant human albumin lyophilized powder.

[0138] The freeze-drying parameters are shown in Table 12.

[0139] Table 12

[0140]

[0141] Example 7

[0142] A formula of a fast-dissolving recombinant human albumin lyophilized powder is shown in Table 13 below.

[0143] Table 13

[0144]

[0145] Referring to Table 13, a method for preparing a fast-dissolving recombinant human albumin lyophilized powder comprises the following steps:

[0146] (1) ultrafiltration, liquid exchange, and salt treatment of the recombinant human albumin solution into purified water (inlet pressure: 30 psi, inlet tangential flow rate: 8.0 LMM, TMP ≤ 25 psi), and diafiltration of the sample according to constant volume dialysis, with a permeate conductivity of <50 μs / cm, to obtain a mixed solution (the recombinant human albumin concentration in the mixed solution is 250 mg / ml), wherein the pore size of the ultrafiltration membrane used in the ultrafiltration treatment is 30 KDa;

[0147] (2) Add sodium octanoate and poloxamer 188 to the mixed solution of step (1), stir and dissolve evenly, then sterilize and filter to obtain a filtrate (sodium octanoate concentration is 20 mg / ml, poloxamer 188 concentration is 21 mg / ml), pre-freeze the filtrate, and then perform sublimation drying and analytical drying to obtain the instant recombinant human albumin lyophilized powder.

[0148] The freeze-drying parameters are shown in Table 14.

[0149] Table 14

[0150]

[0151] Example 8

[0152] A formula of a fast-dissolving recombinant human albumin lyophilized powder is shown in Table 15 below.

[0153] Table 15

[0154]

[0155] As shown in Table 15, a method for preparing a fast-dissolving recombinant human albumin lyophilized powder comprises the following steps:

[0156] (1) ultrafiltration, liquid exchange, and desalination of the recombinant human albumin solution into purified water (inlet pressure: 30 psi, inlet tangential flow rate: 8.0 LMM, TMP ≤ 25 psi), and diafiltration of the sample according to constant volume dialysis, with a permeate conductivity of <50 μs / cm, to obtain a mixed solution (the recombinant human albumin concentration in the mixed solution is 250 mg / ml), wherein the pore size of the ultrafiltration membrane used in the ultrafiltration treatment is 30 KDa;

[0157] (2) Add poloxamer 188 to the mixed solution of step (1), stir and dissolve evenly, then sterilize and filter to obtain a filtrate (poloxamer 188 concentration is 10 mg / ml), pre-freeze the filtrate, and then perform sublimation drying and analytical drying to obtain the instant recombinant human albumin lyophilized powder.

[0158] The freeze-drying parameters are shown in Table 16.

[0159] Table 16

[0160]

[0161] Example 9

[0162] A formula of a fast-dissolving recombinant human albumin lyophilized powder is shown in Table 17 below.

[0163] Table 17

[0164]

[0165] As shown in Table 17, a method for preparing a fast-dissolving recombinant human albumin lyophilized powder comprises the following steps:

[0166] (1) ultrafiltration, liquid exchange, and desalination of the recombinant human albumin solution into purified water (inlet pressure: 30 psi, inlet tangential flow rate: 8.0 LMM, TMP ≤ 25 psi), and diafiltration of the sample according to constant volume dialysis, with a permeate conductivity of <50 μs / cm, to obtain a mixed solution (the recombinant human albumin concentration in the mixed solution is 100 mg / ml), wherein the pore size of the ultrafiltration membrane used in the ultrafiltration treatment is 30 KDa;

[0167] (2) Add acetyltryptophan, sodium octanoate and poloxamer 188 to the mixed solution of step (1), stir and dissolve evenly, then sterilize and filter to obtain a filtrate (acetyltryptophan concentration is 15 mg / ml, sodium octanoate concentration is 40 mg / ml, and poloxamer 188 concentration is 10 mg / ml), pre-freeze the filtrate, and then perform sublimation drying and analytical drying to obtain the instant recombinant human albumin lyophilized powder.

[0168] The freeze-drying parameters are shown in Table 18.

[0169] Table 18

[0170]

[0171] Example 10

[0172] A formula of a fast-dissolving recombinant human albumin lyophilized powder is shown in Table 19 below.

[0173] Table 19

[0174]

[0175] Referring to Table 19, a method for preparing a fast-dissolving recombinant human albumin lyophilized powder comprises the following steps:

[0176] (1) ultrafiltration, liquid exchange, and desalination of the recombinant human albumin solution into purified water (inlet pressure: 30 psi, inlet tangential flow rate: 8.0 LMM, TMP ≤ 25 psi), and diafiltration of the sample according to constant volume dialysis, with a permeate conductivity of <50 μs / cm, to obtain a mixed solution (the recombinant human albumin concentration in the mixed solution is 100 mg / ml), wherein the pore size of the ultrafiltration membrane used in the ultrafiltration treatment is 30 KDa;

[0177] (2) Add acetyltryptophan, sodium octanoate and poloxamer 188 to the mixed solution of step (1), stir and dissolve evenly, then sterilize and filter to obtain a filtrate (acetyltryptophan concentration is 30 mg / ml, sodium octanoate concentration is 40 mg / ml, and poloxamer 188 concentration is 21 mg / ml), pre-freeze the filtrate, and then perform sublimation drying and analytical drying to obtain the instant recombinant human albumin lyophilized powder.

[0178] The freeze-drying parameters are shown in Table 20.

[0179] Table 20

[0180]

[0181] Embodiment 11

[0182] A formula of a fast-dissolving recombinant human albumin lyophilized powder is shown in Table 21 below.

[0183] Table 21

[0184]

[0185] As shown in Table 21, a method for preparing a fast-dissolving recombinant human albumin lyophilized powder comprises the following steps:

[0186] (1) ultrafiltration, liquid exchange, and desalination of the recombinant human albumin solution into purified water (inlet pressure: 30 psi, inlet tangential flow rate: 8.0 LMM, TMP ≤ 25 psi), and diafiltration of the sample according to constant volume dialysis, with a permeate conductivity of <50 μs / cm, to obtain a mixed solution (the recombinant human albumin concentration in the mixed solution is 100 mg / ml), wherein the pore size of the ultrafiltration membrane used in the ultrafiltration treatment is 30 KDa;

[0187] (2) Sodium octanoate and poloxamer 188 are added to the mixed solution of step (1), stirred and dissolved uniformly, and then sterilized and filtered to obtain a filtrate (sodium octanoate concentration is 20 mg / ml, poloxamer 188 concentration is 21 mg / ml), the filtrate is pre-frozen, and then sublimation drying and analytical drying are performed to obtain the instant recombinant human albumin lyophilized powder.

[0188] The freeze-drying parameters are shown in Table 22.

[0189] Table 22

[0190]

[0191] Example 12

[0192] A formula of a fast-dissolving recombinant human albumin lyophilized powder is shown in Table 23 below.

[0193] Table 23

[0194]

[0195] Referring to Table 23, a method for preparing a fast-dissolving recombinant human albumin lyophilized powder comprises the following steps:

[0196] (1) ultrafiltration, liquid exchange, and desalination of the recombinant human albumin solution into purified water (inlet pressure: 30 psi, inlet tangential flow rate: 8.0 LMM, TMP ≤ 25 psi), and diafiltration of the sample according to constant volume dialysis, with a permeate conductivity of <50 μs / cm, to obtain a mixed solution (the recombinant human albumin concentration in the mixed solution is 100 mg / ml), wherein the pore size of the ultrafiltration membrane used in the ultrafiltration treatment is 30 KDa;

[0197] (2) The mixed solution of step (1) is stirred and dissolved uniformly, and then sterilized and filtered to obtain a filtrate, and the filtrate is pre-frozen, and then sublimated and dried to obtain the instant recombinant human albumin lyophilized powder.

[0198] The freeze-drying parameters are shown in Table 24.

[0199] Table 24

[0200]

[0201] Test Case

[0202] Take the instant recombinant human albumin lyophilized powder prepared in Examples 1 to 12 respectively, add purified water to prepare a 200 mg / ml solution, record the corresponding dissolution time, observe, dissolve clarity test, purity test (purity test method reference: 2020 edition of the "Chinese Pharmacopoeia" 0512 high performance liquid chromatography) and dissolution rate test (clarity test method reference: 2020 edition of the "Chinese Pharmacopoeia" 0902 first method. Dissolution rate reference ICH: add lyophilized powder to purified water to prepare a solution with a concentration of 200 mg / ml, redissolve, and start timing to record the time required for the solid to dissolve). At the same time, the moisture content of the lyophilized powder was investigated (moisture content test method reference: 2020 edition of the "Chinese Pharmacopoeia" 0832 first method), and the results are shown in Table 25 below.

[0203] Table 25

[0204]

[0205] It can be seen from the results in Table 25 that the instant recombinant human albumin lyophilized powder prepared by the methods of Examples 1 to 11 can all be quickly dissolved within 100 seconds, and its purity remains unchanged before and after dissolution, and has good resolubility; from the appearance results, it can be concluded that the sample to which sodium octanoate, acetyltryptophan and poloxamer 188 are added at the same time has a white loose crystal shape and the best dissolution effect; the sample to which only one or two of the above excipients are added has a white solid shape and a general dissolution effect; the recombinant human albumin lyophilized powder to which the above excipients are not added has a white solid shape and a poor dissolution effect; under the condition of adding the three excipients at the same time, the solubility of recombinant human albumin at a concentration of 200 mg / ml is better than that of recombinant albumin at concentrations of 100 mg / ml and 250 mg / ml.

[0206] In this example, the recombinant human albumin solution prepared in the dissolution rate experiment was subjected to reduced / non-reduced SDS-polyacrylamide gel electrophoresis (SDS-polyacrylamide gel electrophoresis, referred to as SDS-PAGE). The results of the stability of the reconstituted freeze-dried sample are shown in FIG. Figure 1 , Figure 2 , Figure 3 As shown (Marker spectrum as Figure 4 ), each electrophoresis band is clear and uniform, which also proves that it has good stability and good re-solubility.

[0207] In this example, the instant recombinant human albumin freeze-dried powder prepared in Examples 1 to 12 was also subjected to influencing factor tests (temperature 60°C, humidity 75%, and placed for 6 months) to examine its stability. Afterwards, the instant recombinant human albumin freeze-dried powder after the test corresponding to Examples 1 to 12 was prepared into a solution with a concentration of 0.5 mg / ml, and then analyzed and detected in an HPLC high-performance liquid chromatography instrument with an input volume of 10 μL. The test results are as follows: Figure 5~Figure 16 shown.

[0208] from Figure 5~Figure 15 It can be seen that the recombinant human albumin freeze-dried powder prepared in Examples 1 to 11 has excellent high temperature and high humidity stability, and can be stably stored for more than 5 years at room temperature. The pure albumin dry powder without any excipients has a high impurity content, indicating that the added sodium octanoate, acetyltryptophan and poloxamer 188 have an important influence on the stability of the product.

[0209] Example 13 Single Factor Test of Sodium Octanoate and Acetyltryptophan

[0210] When studying the effect of different concentrations of sodium octanoate on the freeze-dried quality of recombinant human albumin, we set the sodium octanoate to 0 mg / ml, 30 mg / ml, and 60 mg / ml, respectively, and the other conditions were the same as those described in Example 1. Under the corresponding conditions, a single factor experiment of freeze-drying of recombinant human albumin was carried out, and the dissolution rate, appearance and clarity were used as indicators to determine the optimal process for vacuum freeze-drying of recombinant human albumin.

[0211] When studying the effect of different concentrations of acetyltryptophan on the freeze-dried quality of recombinant human albumin, we set the acetyltryptophan to 0 mg / ml, 20 mg / ml, and 40 mg / ml, respectively, and the other conditions were the same as those described in Example 1. Under the corresponding conditions, a single factor test of freeze-drying of recombinant human albumin was carried out, with solubility, shape retention rate and sensory evaluation as indicators. The test method was the same as that described in the test example, the scoring method is shown in Table 26, and the experimental scoring results are shown in Table 27.

[0212] Table 26

[0213]

[0214] Table 27

[0215]

[0216] The experimental scoring results show that the score of the recombinant human albumin freeze-dried powder without sodium octanoate and acetyl tryptophan is 3 points. The dissolution rate of sodium octanoate and acetyl tryptophan is within 200s, and the clarity index is also dissolved. Therefore, the single-factor experiment determines that sodium octanoate and acetyl tryptophan are important auxiliary materials that affect the optimal process of recombinant human albumin freeze-drying.

[0217] The above is only an embodiment of the present application and is not intended to limit the present application. For those skilled in the art, the present application may have various changes and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application should be included in the scope of the claims of the present application.

Claims

1. A method for preparing lyophilized instant recombinant human albumin, characterized in that: The method comprises the following steps: Step 1, ultrafiltration, liquid replacement, and desalination treatment of the recombinant human albumin solution to obtain a mixed solution; Step 2, adding a lyophilization protective agent and a stabilizer to the mixed solution, stirring and dissolving the mixture evenly, sterilizing the mixture to obtain a filtrate, and performing pre-freezing treatment, sublimation drying, and analytical drying on the filtrate to obtain the instant recombinant human albumin lyophilized solution; The lyoprotectant is acetyltryptophan, and the stabilizer is sodium octanoate and poloxamer; the pre-freezing treatment temperature is -55°C~-30°C, and the pre-freezing treatment time is 2~6h; the sublimation drying includes a first sublimation drying treatment and a second sublimation drying treatment; the temperature of the first sublimation drying treatment is -30°C~-20°C, the pressure of the first sublimation drying treatment is 5~35Pa, and the time of the first sublimation drying treatment is 10~25h; the temperature of the second sublimation drying treatment is -25°C~-10°C, the pressure of the second sublimation drying treatment is 5~35Pa, and the time of the second sublimation drying treatment is 10~15h; the desorption drying includes a first desorption drying treatment and a second desorption drying treatment; the temperature of the first desorption drying treatment is 0°C~10°C, the pressure of the first desorption drying treatment is 10~20Pa, and the time of the first desorption drying treatment is 5~25h; the temperature of the second desorption drying treatment is 10°C~20°C, the pressure of the second desorption drying treatment is 2~5Pa, and the time of the second desorption drying treatment is 5~15h; The concentration of the recombinant human albumin is 100-250 mg / ml, the concentration of the acetyltryptophan is 15-30 mg / ml, the concentration of the sodium octanoate is 20-40 mg / ml, and the poloxamer is poloxamer 188, with a concentration of 10-21 mg / ml; The dissolution time of the fast-dissolving recombinant human albumin at a concentration of 200 mg / ml is less than 200 seconds.

2. The method according to claim 1, characterized in that The pore size of the ultrafiltration membrane used in the ultrafiltration is 1-50KDa.

3. Lyophilized instant recombinant human albumin prepared by the method according to claim 1 or 2.

4. A product comprising the freeze-dried instant recombinant human albumin as claimed in claim 3.

5. Use of the method according to claim 1 or 2 in improving the freeze-dried dissolution rate and stability of recombinant human albumin.